Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. has received a temporary approval from the FDA for injectable Carfilzomib, which will become a formal approval after the patent expiration on August 27, 2033, held by Onyx Pharmaceuticals [1] Group 1 - The FDA has granted temporary approval for injectable Carfilzomib to Hainan Puli Pharmaceutical [1] - The formal approval will be contingent upon the expiration of patent US9493582 on August 27, 2033 [1] - Upon patent expiration, the company will be eligible to sell injectable Carfilzomib in the United States [1]